Empatica Achieves CE MDR Certification for EpiMonitor, Bringing Round-the-Clock Epilepsy Monitoring to Europe
EpiMonitor comprises the sophisticated EmbracePlus watch and a companion smartphone app. EpiMonitor's algorithm continuously analyzes user data, looking for patterns that may resemble a generalized tonic-clonic seizure, and sends automated alerts to caregivers with scientifically proven 98% accuracy. EpiMonitor also offers a detailed sleep, activity, and seizure diary, providing people with epilepsy and their doctors with important information to make empowered decisions on their health journey.
EpiMonitor is now available in Germany, France, Italy, Spain, Denmark, Sweden, Belgium, Luxembourg, Austria, Liechtenstein, Ireland, the Netherlands, Malta, and Finland. The EpiMonitor app is also available in all local languages for a seamless experience for its users.
"EpiMonitor's availability in Europe is a great milestone for the epilepsy community," said Simone Tognetti, Empatica's CTO & Co-founder. "Our goal is to continue bringing technology that improves lives to more people around the world. EpiMonitor is the world's only non-invasive, medical-grade wearable for night and day epilepsy monitoring, and our rigorous engineering methods and quality processes guarantee unmatched safety and accuracy. With EpiMonitor, we have taken the best of our previous wearables and amplified it in a solution that uses our most innovative and powerful technology, alongside algorithms that provide detailed and meaningful health insights. We didn't want to make just another health tracker, but to provide a lifeline for the millions of people living with epilepsy around the world."
Key features of EpiMonitor include:
Fully medical-grade technology consisting of a wearable and app
Automatic generalized tonic-clonic seizure detection and alerts to caregivers (98% accuracy; low False Alarm Rate)
Ability for users to send self-triggered alerts to caregivers
Up to 7 days of battery life
A user-friendly mobile app with a detailed, automated diary
Daily sleep and activity tracking through Empatica's algorithms
Detailed reports that can be exported and shared with a doctor
High accessibility with app translations in 8 languages
Compatibility with iOS and Android smartphones
Empatica has been the market leader in providing the world's only medical watches for people living with epilepsy for nearly a decade. Epilepsy affects 6 million people in Europe, with approximately 15% of those being children. Studies indicate that up to 40% of epilepsy cases are difficult to treat, and a third of people with epilepsy are refractory to current medications. Sudden Unexpected Death in Epilepsy (SUDEP) is the number one cause of epilepsy-related deaths in people with pharmacoresistant epilepsy. Most SUDEP deaths occur when a generalized tonic-clonic seizure occurs during sleep.
EpiMonitor can be purchased directly from the Empatica website. To learn more visit empatica.com/epimonitor.
Empatica Inc is a pioneer in continuous, unobtrusive remote health monitoring driven by AI. Empatica's platform and technology are used by thousands of institutional partners for research purposes, in studies examining stress, sleep, epilepsy, migraine, depression, addiction, and other conditions. In 2018, Empatica's Embrace wearable received FDA clearance for seizure monitoring, making it the world's first epilepsy watch to be cleared by the FDA. Its successor, EpiMonitor, launched in the US in 2024 after receiving FDA clearance. Empatica's flagship medical wearable, EmbracePlus, has been developed with key partners including HHS, USAMRDC, and NASA.
View source version on businesswire.com: https://www.businesswire.com/news/home/20250414434006/en/
Contacts
Marianna Xenophontospress@empatica.com
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Gizmodo
2 minutes ago
- Gizmodo
We Now Know Everything About the First Xbox Handheld (Except the Most Important Thing)
The Asus ROG Xbox Ally is a mouthful of a name for a device, and yet I can't stop saying the name—like I'm casting a spell—as we slide further toward the end of the year. At Gamescom in Cologne, Germany, Microsoft and Asus are giving players a chance to wrap their mitts around the strange Xbox controller-like grips of the Xbox Ally and Xbox Ally X. While the companies will tell you when you'll eventually be able to pick one off a store shelf, they're not quite ready to tell you how much it'll cost. Both the ROG Xbox Ally and ROG Xbox Ally X are slated for release on Oct. 16 in the U.S., Europe, and other markets in Asia. We won't know how much it will cost and when we can preorder one until sometime 'in the coming weeks,' Asus said in a press release. Gamescom attendees will be first to try out the new Xbox-ified version of Windows 11, which should make it easier than Microsoft's regular ol' OS to launch games on both the Xbox app and through third-party launchers like Steam and Epic Games Store. The handheld effectively dual boots into the base version of Windows 11 if you need to access all the apps you can't from the new Xbox menu. Microsoft is also working on a 'Handheld Compatibility Program' akin to Valve's Steam Deck Verified badges. Xbox will label whether a game is 'handheld optimized,' which means it works with the default controller layout, or 'mostly compatible,' which will require a few adjustments. The ROG Xbox Ally is the lower-end starter handheld compared to the beefier specs of the Xbox Ally X. The one in white comes packed with an AMD Ryzen Z2 A processor. Based on specs alone, the chip seems closest in power to a Steam Deck. It's a 4-core, 8-thread chip based on AMD's Zen 2 microarchitecture, which the chipmaker launched back in 2019. It's running on eight RDNA 2 GPU cores, which should be enough for the vast majority of smaller games and a fair few AAA titles on lower graphics settings. It still comes with 16GB of RAM and 512GB of built-in storage. The Xbox Ally X is the one that comes packed with AMD's Ryzen Z2 Extreme. That APU, or accelerated processing unit, sports 8 cores and 16 threads based on AMD's latest Zen 5 CPU architecture. The chip is packed with 16 RDNA 3.5 GPU cores—though not the latest RDNA 4—alongside 32GB of RAM and 1TB of storage. Just like the Asus ROG Ally X from 2024, it contains an 80Wh battery that should enhance overall playtime, depending on your performance settings. Microsoft also hinted the Xbox Ally X will make use of Microsoft's Automatic Super Resolution for on-device AI upscaling to enhance performance. Both the Xbox Ally and Ally X contain a 7-inch LCD display. Microsoft said either handheld should receive future updates that will allow for faster launching and better battery life, as well as 'enhancements to the docking experience' that suggest the Xbox Ally will work better connected to a monitor or TV. There are a few reasons you should be concerned that neither Microsoft nor Asus wants to drop the bombshell that is pricing. We caught a hint of supposed Xbox Ally prices for European customers back in July. The Xbox Ally was set at 600 euros, or $700, while the Xbox Ally X demanded 900 euros, or $1,050. Those are similar prices to today's ROG Ally and ROG Ally X in the EU, so these leaks may not be equivalent to what U.S. customers can expect to pay. Tariffs have already caused havoc on PC supply chains and led to manufacturers raising prices. Without any official notice, Asus raised prices on its ROG Ally X from $900 to $1,000 a few months after President Donald Trump announced sweeping global tariffs. Optimists will look at the delayed pricing and hope Microsoft is working out a way to subsidize what will be its first new gaming hardware in years, even if it's simply sporting the Xbox brand name. If the Xbox Ally X is truly as pricey as other handheld PCs, it would make it a premium product that only the most ardent PC gamers would be willing to fork over their funds for. It will need to compete with upcoming handhelds like the Lenovo Legion Go 2 that sports a better OLED display compared to the Ally's LCD. The Xbox Ally needs to be, at the very least, as cheap as a baseline Steam Deck OLED at $550 or the $600 Lenovo Legion Go S if Asus and Xbox want any chance of staking a claim in the still-nascent handheld scene.
Digital Trends
2 minutes ago
- Digital Trends
We know when the ROG Xbox Ally X will hit store shelves, but the price tag is still a mystery
The drip feed of information regarding the ROG Xbox Ally X continues through Gamescom as we finally learn the handheld's official release date, but Asus and Xbox have yet to drop the price on us. Hitting store shelves on October 16, we are still completely in the dark as to when we can preorder the latest handheld or if we will even be able to afford one. Xbox had a massive presence at Gamescom this year, but opted to dedicate a huge booth to demoing games not on its traditional hardware, but instead the upcoming ROG Xbox Ally X. Officially announced earlier this year, rumors have been circulating about how much this powerful handheld would cost. Among the excitement of seeing Silksong and other games demoed on the new device, the only new bit of information we got was that the system will be available on October 16, less than two months from now, which makes the lack of any price information even more concerning. Recommended Videos Price and preorder information are promised to be coming in the coming weeks. The ROG Xbox Ally X is the latest handheld gaming device aiming to compete with the likes of the Steam Deck and Switch 2. Previous ROG handhelds have been well received for their power, but aren't as user-friendly as home consoles. Partnering with Xbox, this new iteration will have an overhauled UI that more closely mimics a console experience rather than present itself like a handheld PC. It will allow players to easily download and play games from all major PC storefronts, including Steam, Epic, and Xbox Game Pass. The excitement of learning the release date is certainly dampened by not being able to preorder the device like we all thought we would, and the lack of an official price might mean the leaked prices of around $700 for the ROG Xbox Ally and over $1,000 for the X could be accurate. Of course, with the ever-changing economic landscape and tariff policies, we might need to brace for even higher prices.
Yahoo
37 minutes ago
- Yahoo
Madrigal wins European MASH approval as Novo rivalry looms
Madrigal Pharmaceuticals' Rezdiffra (resmetirom) has been approved in Europe for the treatment of metabolic dysfunction-associated steatohepatitis (MASH) with moderate to advanced liver fibrosis, making it the first targeted therapy available for patients in the region with this severe form of liver disease. The conditional marketing authorisation by the European Commission (EC) follows an approval recommendation by the European Medicines Agency (EMA)'s Medicinal Products for Human Use (CHMP) in June. US pharma Madrigal expects to launch Rezdiffra in Europe on a country-by-country basis, starting with Germany in Q4 2025, as per a 19 August statement. Stock in US-listed Madrigal closed 2.2% down to $379.55 per share at market close on 19 August, with investors likely downbeat amid a tangential development. Viking's oral glucagon-like peptide-1 receptor agonist (GLP-1RA) drug posted disappointing trial results on the same day; Madrigal recently outlaid $2bn in an oral GLP-1RA licensing deal. The regulatory approval means Madrigal is the only pharmaceutical company with an approved MASH drug in Europe. Rezdiffra was also the first MASH treatment to market in the US – winning US Food and Drug Administration (FDA) approval in March 2024. MASH develops when there is a significant buildup of fat in the liver. Fibrosis, also known as scarring, is associated with MASH, and left untreated, it can lead to more serious damage, including cirrhosis. Madrigal estimates that approximately 370,000 patients have been diagnosed with MASH with moderate to advanced fibrosis in Europe. The disease is a form of non-alcoholic fatty liver disease (NAFLD) that has been billed as one of pharma's highest potential growth areas. Analysis by GlobalData forecasts sales of $25.7bn in 2032 across the seven major markets (the US, France, Germany, Italy, Spain, the UK, and Japan), meaning Madrigal's first-to-market credentials in both the US and Europe could bode well for the drug's growth. GlobalData forecasts a high ceiling for Rezdiffra. The drug is expected to reach blockbuster status by the end of 2026, and, by 2031, Rezdiffra is forecast to generate $4.8bn in global sales. GlobalData is the parent company of Pharmaceutical Technology. Administered as a daily pill, Rezdiffra works by activating a thyroid hormone receptor that reduces liver fat accumulation. While Madrigal was first to reach market in the US for a MASH treatment, it has since lost its crown of boasting the only approved therapy in the indication. Earlier this week, Novo Nordisk's blockbuster drug Wegovy (semaglutide) won FDA approval for the treatment of MASH with moderate to advanced liver fibrosis, providing direct competition to Rezdiffra. Novo Nordisk has also applied for regulatory approval in the EU, setting up a second potential rivalry with Madrigal. However, unlike Wegovy, which exerts its effect through agonism of the GLP-1 receptors, Madrigal's treatment works directly in the liver itself. GlobalData senior analyst Jay Patel says: "This approval allows Madrigal's Rezdiffra to establish an early lead in the EU MASH market. Nevertheless, Novo Nordisk's Wegovy is set to follow closely behind, with an approval expected imminently. "It remains to be seen whether Rezdiffra will be able to carve out a niche once this takes place, given greater patient and physician familiarity with Wegovy, which is already approved for common MASH comorbidities such as obesity and type 2 diabetes mellitus." The EC based its approval on results from the Phase III MAESTRO-NASH trial, in which Rezdiffra achieved both fibrosis reduction and MASH resolution primary endpoints. The pill also reduced liver stiffness, liver fat, liver enzymes, and atherogenic lipids in the MAESTRO-NASH trial, and improved health-related quality of life. Madrigal's CEO Bill Sibold said: 'MASH is the fastest-growing indication for liver transplantation in Europe, but until now, it had no approved treatment. The European labelling for Rezdiffra will set an important precedent for the entire field, with no biopsy required to qualify for treatment with Rezdiffra and a clear focus on a distinct MASH patient population with high unmet need.' Before Madrigal and Novo's approvals, MASH had become a graveyard of failed candidates. Gilead, AstraZeneca, and Intercept all fell short in getting candidates to market, all eventually pivoting pipelines away from the indication. "Madrigal wins European MASH approval as Novo rivalry looms" was originally created and published by Pharmaceutical Technology, a GlobalData owned brand. The information on this site has been included in good faith for general informational purposes only. It is not intended to amount to advice on which you should rely, and we give no representation, warranty or guarantee, whether express or implied as to its accuracy or completeness. You must obtain professional or specialist advice before taking, or refraining from, any action on the basis of the content on our site. Sign in to access your portfolio
